Journal of Functional Foods (Oct 2022)

Effects of erinacine A-enriched Hericium erinaceus on elderly hearing-impaired patients: A double-blind, randomized, placebo-controlled clinical trial

  • Yin-Ching Chan,
  • Tzu-Chun Lin,
  • Chin-Chu Chen,
  • Li-Ya Lee,
  • Wan-Ping Chen,
  • Ya-Zue Liu,
  • Juen-Haur Hwang

Journal volume & issue
Vol. 97
p. 105220

Abstract

Read online

We aimed to investigate the effects and mechanisms of Hericium erinaceus (HE) on hearing degeneration. By a double-blind, randomized, clinical trial, all 80 hearing-impaired patients aged 50–79 were randomly divided into the two groups, which received HE mycelia (2000 mg/day) and placebo boluses for eight months, respectively. A student’s t-test was used to evaluate the differences of the average pure tone hearing threshold of all, low, and high frequencies (PTA-all, PTA-low, and PTA-high); speech recognition threshold (SRT); speech discrimination score (SDS); and serum concentrations of brain-derived neurotrophic factor (BDNF) and neurotrophic growth factor (NGF) between the two study groups. Subgroup analysis by age showed that PTA-high-Right, PTA-all-Left, PTA-high-Left, SRT-Right, SRT-Left, and NGF were significantly different between the two groups among patients aged ≧ 65. HE mycelia treatment could ameliorate hearing loss, especially for high frequencies and speech recognition, and increase NGF in patients aged ≧ 65.

Keywords